In a study of 444 patients, the firm and its collaborators identified a six-protein panel that provided improved predictive power compared to clinical measures.
The lawsuit, filed in 2015 against Accelerate and some of its executives alleging false and misleading statements, was dismissed after the plaintiffs requested the action.
T2 Biosystems' device will potentially enable 95 percent of patients with bloodstream infections to receive targeted therapy within eight hours of a blood draw.
During a clinical study, a positive antimicrobial stewardship outcome emerged in 74 percent of cases where the firm's test provided a rule-out result for sepsis.
As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.
